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AbstrACt
Introduction Stroke is the most disabling neurological 
disorder and often causes spasticity. Transmucosal 
cannabinoids (tetrahydrocannabinol and cannabidiol 
(THC:CBD), Sativex) is currently available to treat 
spasticity-associated symptoms in patients with multiple 
sclerosis. Cannabinoids are being considered useful 
also in the treatment of pain, nausea and epilepsy, but 
may bear and increased risk for cardiovascular events. 
Spasticity is often assessed with subjective and clinical 
rating scales, which are unable to measure the increased 
excitability of the monosynaptic reflex, considered the 
hallmark of spasticity. The neurophysiological assessment 
of the stretch reflex provides a precise and objective 
method to measure spasticity. We propose a novel study to 
understand if Sativex could be useful in reducing spasticity 
in stroke survivors and investigating tolerability and safety 
by accurate cardiovascular monitoring.
Methods and analysis We will recruit 50 patients with 
spasticity following stroke to take THC:CBD in a double-
blind placebo-controlled cross-over study. Spasticity will 
be assessed with a numeric rating scale for spasticity, the 
modified Ashworth scale and with the electromyographical 
recording of the stretch reflex. The cardiovascular risk will 
be assessed prior to inclusion. Blood pressure, heart rate, 
number of daily spasms, bladder function, sleep disruption 
and adverse events will be monitored throughout the 
study. A mixed-model analysis of variance will be used to 
compare the stretch reflex amplitude between the time 
points; semiquantitative measures will be compared using 
the Mann-Whitney test (THC:CBD vs placebo) and Wilcoxon 
test (baseline vs treatment).
Ethics and dissemination The study was registered 
on the EudraCT database with number 2016-001034-
10 and approved by both the Italian Medicines Agency 
(Agenzia Italiana del Farmaco) and local Ethics Committee 
‘Comitato Etico Regionale della Liguria’. Data will be made 
anonymous and uploaded to a open access repository. 
Results will be disseminated by presentations at national 
and international conferences and by publication in 
journals of clinical neuroscience and neurology.
IntroduCtIon
Stroke is one of the most disabling neuro-
logical disease and frequently determines 
important chronic consequences such as 
spasticity. Prevalence of poststroke spasticity 
ranges from 4% to 42.6%, with the preva-
lence of disabling spasticity ranging from 2% 
to 13%.1 Treatment of poststroke spasticity 
is based on rehabilitation, local injection 
of botulinum toxin (BoNT) in the affected 
muscles for focal spasticity and/or use of 
classic oral drugs such as tizanidine, baclofen, 
thiocolchicoside and benzodiazepines, which 
are not always effective and have a good 
number of possible side effects.
The transmucosal administration of 
delta-9-tetrahydrocannabinol and cannabi-
diol (THC and CBD at 1:1 ratio oromucosal 
spray, Sativex) is able to reduce spasticity 
acting on endocannabinoid receptors CB1 
and CB2. This novel drug has been licensed 
after an extensive clinical trial programme2–4 
in adult patients with multiple sclerosis who 
have shown no significant benefit from other 
antispasmodic drugs. More than 45 000 
patient/years of exposure since its approval 
in more than 15 EU countries support their 
antispasticity effectiveness and safety profile 
strengths and limitations of this study
 ► First study on Sativex to treat poststroke spasticity.
 ► Electromyographical recording of the stretch reflex 
to precisely measure spasticity.
 ► Assessment of cannabinoids tolerability in stroke 
survivors.
 ► Limited number of patients in relation to a 
monocentric pilot study.
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in this indication.5 Besides improving spasticity, canna-
binoids can be beneficial in reducing pain, chemo-
therapy-induced nausea and vomiting; moreover, they 
contribute to reducing seizures and to lowering eye pres-
sure in glaucoma.6 Cannabinoids can also exert psycho-
logical effects by lowering anxiety levels and inducing 
sedation or euphoria. Marijuana, which is the main 
source of cannabinoids, is declared illegal in many coun-
tries mostly because of the risk of abuse, dependence 
and withdrawal syndrome, related to the effect of its high 
amounts of THC. Several reports support an increased 
ischaemic stroke risk related to relevant abuse of smoked 
marijuana7–17 as well as synthetic cannabinoids.18–20 Isch-
aemic stroke following cannabis involves more frequently 
basal ganglia and cerebellum where CB1 and CB2 recep-
tors show a higher expression.13
The ‘French Association of the Regional Abuse and 
Dependence Monitoring Centres Working Group on 
Cannabis Complications’ warns about the increased 
cardiovascular risk related to the use of herbal cannabis, 
mostly consisting of acute coronary syndromes and periph-
eral arteriopathies, potentially leading to life-threatening 
conditions.21 The detrimental consequences of cannabi-
noids could be attributed to the increase in heart rate22 as 
well as arterial spasms also in the context of a reversible 
cerebral vasoconstriction syndrome,23 but also vasculitis, 
postural hypotension and cardioembolism.24
On the other side, some studies support a beneficial 
effect on stroke evolution of cannabinoid receptors stim-
ulation. In fact, cannabinoid-mediated activation of CB1 
and CB2 receptors reduces inflammation and neuronal 
injury in acute ischaemic stroke.25 Activation of CB2 
receptors shows protective effects after ischaemic injury26 
and inhibits atherosclerotic plaque progression.27 28
To our knowledge, no correlations have been reported 
between haemorrhagic stroke and cannabinoids intake. 
In our opinion, the modification of blood pressure is 
the most important cannabinoid effect that should be 
taken into account in patients with a previous haemor-
rhagic stroke or predisposed to intracranial bleeding. 
Cannabinoids are indeed capable of inducing blood 
pressure fluctuations in a specific triphasic pattern 
(low-high-low) potentially harmful if the patient is with 
bleeding risk.29 Ischaemic disease is not included among 
THC:CBD oromucosal spray contraindications. However, 
considering that, to our knowledge, no study has been 
performed with THC:CBD oromucosal spray on post-
stroke spasticity, we believe that a particular caution 
should be used in stroke patients.
The decision of which method of measure is consid-
ered as end point is a major issue in studies involving 
spasticity. The definition of spasticity provided by Lance 
is one of the most precise and reliable, focusing on the 
stretch reflex as the neurophysiological equivalent of 
spasticity.30 Probably because of technical complexity 
and required expertise, neurophysiological approaches 
are rarely adopted. Clinical rating scales such as the 
modified Ashworth scale (MAS)31 or subjective scores 
such as the numeric rating scale (NRS) for spasticity are 
being widely used.32 33 Recent evidence supports the idea 
that MAS and NRS are indeed useful to quickly rate spas-
ticity in a clinical setting, however NRS provide a very 
variable and imprecise assessment of many symptoms 
related to spasticity, but where spasticity itself is probably 
only a common factor.34 The adoption of stretch reflex 
as the most appropriate neurophysiological measure of 
spasticity increases the specificity and reduces the vari-
ability of the end point and is particularly suitable for 
clinical trials.
Our proposal is therefore to assess the efficacy of 
THC:CBD oromucosal spray in patients with spasticity 
following stroke as add-on to first-line antispasticity medi-
cations with an experimental pilot randomised place-
bo-controlled cross-over clinical trial using the stretch 
reflex as primary outcome measure. Prior to inclusion in 
the study, we propose strict selection criteria in order to 
reduce the risk of relevant side effects.
Methods and analysis
Subjects
At the Department of Neuroscience of the ‘Ospedale Poli-
clinico San Martino’, we will recruit 50 patients with spas-
ticity secondary to stroke that occurred at least 3 months 
earlier. Both naïve to BoNT or BoNT-treated patients will 
be recruited; however, those treated with BoNT will enter 
the study at least 4 months after the last injection in order 
to allow a reasonable washout. The study will last 2 years.
Inclusion criteria are:
 ► Presence of spasticity rated between 1 and 3 at the 
MAS in at least one of the following segments: flexor 
muscles of the wrist, flexor muscles of the elbow, 
extensor muscles of the leg and/or foot plantar 
flexors;
 ► Absence of significant peripheral nervous system 
pathology detectable on clinical basis;
 ► Absence of concomitant parkinsonism;
 ► Acceptable cardiovascular ischaemic risk following a 
cardiological evaluation along with the laboratory and 
instrumental examinations requested by the cardiolo-
gist, as well as a CHA2DS2VASc score (currently used to 
estimate the risk of stroke in patients with non-rheu-
matic atrial fibrillation) less than 7;
 ► Absence of a demonstrated stenosis higher than 50% 
at intracranial main arteries (mean cerebral, basilar, 
internal carotid, vertebral) or at cervical tracts of 
carotid and vertebral arteries;
 ► Absence of significant cognitive impairment 
hampering patients’ capability of understanding the 
study protocol and signing the consent form;
Apart from the criteria listed above, there will be no 
limitations related to age, sex and degree of disability.
The following sociodemographic data will be collected: 
gender, age, time of acute lesion, years with spasticity, 
areas affected with spasticity.
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study protocol
Patients will enter a cross-over study paradigm after a 
cardiac-cerebral-vascular risk assessment performed by a 
cardiologist and by a vascular neurologist; those with an 
acceptable cardiac-cerebral-vascular risk will be randomly 
assigned (in a 1:1 ratio) to one of the two following treat-
ment sequences (figure 1):
 ► THC:CBD oromucosal spray—placebo (ie, THC:CBD 
oromucosal spray during period I and placebo during 
period II)
 ► Placebo—THC:CBD oromucosal spray (ie, placebo 
during period I and THC:CBD oromucosal spray 
during period II)
The randomisation list will be generated through a vali-
dated SAS programme, in permuted blocks of reasonable 
size in order to guarantee the treatment balance.
After the first (T0) baseline evaluation visit, during the 
1-month period, the patients will titrate their medication 
to reach the optimal number of puffs/day and then evalu-
ated again (T1). A 2 weeks washout time will allow patients 
taking THC:CBD oromucosal spray (or placebo) to reach 
their baseline spasticity condition and then patients will 
switch arms and perform another month for the other 
treatment. After a while, the final (T2) assessment will be 
performed. During the whole study, the patients will have 
to maintain the same therapy apart from the study drug 
in order to minimise other conditions that could affect 
the level of spasticity. For the same reason, patients are 
required not to undergo any physical and rehabilitative 
treatment during the study. During T1 and T2 evaluation, 
additional information about the number of sprays/day 
will be collected, along with all possible adverse events. 
During the 10 weeks of the study, patients not responding 
to the treatment and unable to complete the study 
untreated will undergo a rescue treatment (eg, BoNT) 
and exit the study. All patients will be monitored by a 
neurological clinical follow-up at least for 1 year on study 
termination.
This is a double-blind study. All individuals involved in 
the study conduct, including patients, investigator staff, 
persons performing the assessments and data analysts will 
remain blinded to the identity of the treatment from the 
time of randomisation until database lock.
Randomisation data will be kept strictly confidential 
until the time of unblinding and will not be accessible 
to anyone involved in the conduct of the study. The 
identity of the treatments will be concealed by the use of 
study drugs (THC:CBD oromucosal spray and matching 
placebo) that are identical in packaging, labelling, 
schedule of administration and in appearance.
At the conclusion of the study, when the database has 
been locked, the assigned blinded treatment codes will be 
broken and made available for the final statistical analysis.
Individual patient unblinding during the course of the 
trial will only be allowed in the event of patient emergen-
cies on request from the investigator.
Experimental procedure
Preliminary setting and clinical evaluation
After the selection process and informed consent signa-
ture, all subjects will undergo a complete physical and 
neurological examination. The range of motion and MAS 
of the following segments will be assessed on both sides: 
elbow flexors, forearm pronators, wrist flexors, finger 
flexors, leg extensors, foot plantar flexor. The subjective 
amount of pain and muscle rigidity, quality of sleep and 
bladder dysfunction will be assessed using a 0–10 NRS, 
as well as the number of daily spasms. The amount of 
disability related to hygiene, dressing, limb position and 
pain will be also assessed by mean of the Disability Assess-
ment Scale.35
Blood pressure and heart rate will also be evaluated 
during each scheduled visit and the patient's diary will 
be checked. The participants will be instructed about 
the medication dose uptitration process, patients’ diary 
fulfilment and next visit date. All patients will be given a 
Figure 1 Graphical representation of the study protocol, particularly depicting the cross-over design and the time points. THC/
CBD, tetrahydrocannabinol/cannabidiol.
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portable blood pressure device and instructed to record 
daily blood pressure values at home.
Possible adverse events will be monitored during the 
entire duration of the study. The detailed schedule of 
assessments and procedures is reported in table 1.
Stretch reflex technical setup
The Biopac MP150 data acquisition system connected 
to a TSD130B twin-axis electronic goniometer (Biopac 
Systems, Goleta, CA, USA) will be used for data acquisi-
tion. The goniometer will be placed across the joint in 
order to optimally record the angle during the displace-
ments with a sampling rate of 2 KHz. Electromyographic 
(EMG) activity produced by the stretched muscle will 
be recorded by surface electrodes (TSD150B, Biopac 
Systems) placed over the muscle belly. Movement timing 
will be paced by a software emulated metronome.
The subjects will be evaluated in a quiet room with a 
temperature between 21°C and 23°C. A limb segment 
presenting with spasticity between 1 and 3 at the MAS 
will be selected among flexor muscles of the wrist, flexor 
muscles of the elbow, extensor muscles of the leg, foot 
plantar flexor. If spasticity is detectable in more segments, 
in order to cause less discomfort to patients and exam-
iners and prefer the choice of joints with a higher range 
of motion (allowing more accurate passive movement 
timing), the segments will be selected in the following 
order: wrist flexors, elbow flexors, leg extensors, foot 
plantar flexors (defined ‘selected segment’ and under-
going the stretch reflex procedure). For example, if 
a patient is affected by spasticity on both wrist flexors 
(MAS=2) and leg extensors (MAS=3), the stretch reflex 
procedure will be performed on wrist flexors. The subject 
will be seated if the selected segment is flexor muscles 
of the wrist, flexor muscles of the elbow; otherwise, the 
subject will be lying on a comfortable examination table in 
a supine (extensor muscles of the leg) position with head 
and shoulders slightly elevated, or prone (foot plantar 
flexors) with the feet protruding from the examination 
table in order to allow a full ankle range of movement.
Stretch reflex procedure
The method was described in detail in the first validating 
work.36 The method consists in moving the selected 
segment throughout the full range of motion in the 
time corresponding to the interval between two consec-
utive metronome tones. The increase or decrease of 
tone frequency (beats per minute (BPM)) determines 
a parallel change in the time required to perform a 
complete passive flexion or extension movement, so that 
given a certain range of motion, the mean movement 
velocity will be similarly modulated. The choice of the 
Table 1 Schedule of assessments and procedures
Study Period
Screening and 
randomization Period I Wash-out Period II
Visit 1 (T0) 2 (T1) 3 4 (T2)
Informed consent X
Demography X
Medical and treatment history X
Physical and neurological examination X X X X
Full cardio evaluation X
Cardio consultation ‘as needed’ X X X
Vital signs X X X X
Inclusion and exclusion criteria X
Modified Ashworth scale X X X
Spasticity NRS X X X
Stretch reflex evaluation X X X
Check patients diary X X
  Spasticity NRS, Pain NRS, Bladder dysfunction NRS X X
  Spasms number X X
  Sleep quality NRS X X
  Blood pressure and heart rate X X
Dispense study drug X X
Check of returned study drug X X
Adverse events X X X
Concomitant medications X X X X
NRS, numerical rating scale.
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BPM will be done taking into account that low values 
could not be able to elicit a stretch reflex (especially in 
subjects with a low degree of spasticity), while high values 
could produce discomfort to the subject and excessive 
fatigue in the examiner. Continuous flexion and exten-
sion movements in a ‘sinusoidal’ way may be unsuitable 
to elicit and measure spasticity because of the possibility 
to trigger postactivation depression37 or paratonia.38 
However, the method allows performing discontinuous 
(or ‘linear’) movements as well, by interposing a few 
tones interval between movements.
The subjects will be instructed to remain relaxed and to 
avoid resisting or facilitating the movements performed 
by the examiner. The stretch reflexes will be measured 
during movements determining elongation of the spastic 
muscle. At least 15 discontinuous stretch reflexes will be 
acquired during each experimental session. The record-
ings will be performed at each time point (T0, T1, T2) 
using the same metronome BPM. In order to obtain a 
reproducible electrode positioning between sessions, 
a picture of the electrode and its relation with nearby 
anatomical landmarks will be taken in each subject at T0. 
In order to reduce variability, the examiner performing 
the passive movements will be the same in all time points 
for each patient.36
data analysis
The main end points of the study will be to assess the 
effect of THC:CBD oromucosal spray on spasticity 
measured with the stretch reflex and NRS for spasticity. 
To analyse the stretch reflex, the electromyographical 
recordings will be filtered, rectified and the average 
amplitude of the bursts will be calculated (mean EMG) 
using the dedicated AcqKnowledge analysis software 
(Biopac Systems). A mixed-model analysis of variance 
with GROUP (THC:CBD oromucosal spray, placebo) as 
between-subjects factor and TIME (T0, T1, T2) as with-
in-subjects factor will be used to compare mean EMG 
values.
All semiquantitative rating scales scores will be 
compared between THC:CBD oromucosal spray/placebo 
groups using the Mann-Whitney test at each evaluation 
(T0, T1, T2). A comparison between T0 and T1 as well as 
between T0 and T2 will also be performed in each group 
using Wilcoxon test.
Since this is a pilot study, no formal sample size calcu-
lation can be done. It must be noticed, however, that in 
our previous study on patients with multiple sclerosis, 
we detected a significant reduction of the stretch reflex 
analysing 36 subjects.34
EthICs And dIssEMInAtIon
The study was registered on the EU Clinical Trials 
Register (EudraCT) database with number 2016-
001034-10 and named ‘SativexStroke’. We received the 
approval from the Italian Medicines Agency (Agenzia 
Italiana del Farmaco) on 23 September 2016, the 
approval from the local Ethics Committee ‘Comitato 
Etico Regionale della Liguria’ on 14 December 2016 
(protocol V.4.2) and the authorisation from ‘Ospedale 
Policlinico San Martino’ hospital on 3 March 2017 
(decree number 227).
We plan to start patient recruitment in October 
2017, after the drug has been produced and labelling 
completed. All study-related information will be stored 
securely at the study site and all participant informa-
tion will be stored in locked file cabinets in areas with 
limited access. Electromyographical recordings and all 
the study-related files will be stored on a password-pro-
tected personal computer.
During the study, only the principal investigator will 
have access to the full data set. The final trial dataset will 
be blinded of any identifying participant information and 
uploaded to an open access data repository. The anal-
ysis will be probably completed by the end of 2019, after 
the 2-year study period. The data will be disseminated by 
presentation at national and international conferences 
and by publication in journals of clinical neuroscience 
and neurology.
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